|
1
|
Inaba H, Greaves M and Mullighan CG: Acute
lymphoblastic leukaemia. Lancet. 381:1943–1955. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Puumala SE, Ross JA, Aplenc R and Spector
LG: Epidemiology of childhood acute myeloid leukemia. Pediatric
Blood Cancer. 60:728–733. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang N, Wen D, Wang T and Deng J:
Disparities in incidence and mortality of pediatric acute
lymphoblastic leukemia across countries with different incomes.
Leukemia. October 4–2024.(Epub ahead of print). View Article : Google Scholar
|
|
4
|
Lupo PJ and Spector LG: Cancer progress
and priorities: Childhood cancer. Cancer epidemiology, biomarkers
& prevention: A publication of the American Association for
Cancer Research, cosponsored by the American Society of Preventive
Oncology. 29:1081–1094. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Faderl S, O'Brien S, Pui CH, Stock W,
Wetzler M, Hoelzer D and Kantarjian HM: Adult acute lymphoblastic
leukemia: Concepts and strategies. Cancer. 116:1165–1176. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Redaelli A, Laskin BL, Stephens JM,
Botteman MF and Pashos CL: A systematic literature review of the
clinical and epidemiological burden of acute lymphoblastic
leukaemia (ALL). Eur J Cancer Care (Engl). 14:53–62. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tzoneva G, Perez-Garcia A, Carpenter Z,
Khiabanian H, Tosello V, Allegretta M, Paietta E, Racevskis J, Rowe
JM, Tallman MS, et al: Activating mutations in the NT5C2
nucleotidase gene drive chemotherapy resistance in relapsed ALL.
Nat Med. 19:368–371. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fielding AK, Richards SM, Chopra R,
Lazarus HM, Litzow MR, Buck G, Durrant IJ, Luger SM, Marks DI,
Franklin IM, et al: Outcome of 609 adults after relapse of acute
lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study.
Blood. 109:944–950. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sas V, Moisoiu V, Teodorescu P, Tranca S,
Pop L, Iluta S, Pasca S, Blag C, Man S, Roman A, et al: Approach to
the adult acute lymphoblastic leukemia patient. J Clin Med.
8:11752019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bansal M, Sharma KK, Bakhshi S and Vatsa
M: Perception of Indian parents on health-related quality of life
of children during maintenance therapy of acute lymphoblastic
leukemia: A comparison with siblings and healthy children. J
Pediatr Hematol Oncol. 36:30–36. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Reinfjell T, Lofstad GE, Nordahl HM, Vikan
A and Diseth TH: Children in remission from acute lymphoblastic
leukaemia: Mental health, psychosocial adjustment and parental
functioning. Eur J Cancer Care (Engl). 18:364–370. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Khalifa AS, Bishry Z, Tantawy AAG, Ghanem
MH, Effat SM, Shahawy HE and Ebeid FSE: Psychiatric morbidity in
Egyptian children with acute lymphoblastic leukemia and their care
providers. Hematol Oncol Stem Cell Ther. 7:76–84. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kantarjian H, Thomas D, O'Brien S, Cortes
J, Giles F, Jeha S, Bueso-Ramos CE, Pierce S, Shan J, Koller C, et
al: Long-term follow-up results of hyperfractionated
cyclophosphamide, vincristine, doxorubicin, and dexamethasone
(Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic
leukemia. Cancer. 101:2788–2801. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mantadakis E, Cole PD and Kamen BA:
High-dose methotrexate in acute lymphoblastic leukemia: Where is
the evidence for its continued use? Pharmacotherapy. 25:748–755.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schmiegelow K, Nielsen SN, Frandsen TL and
Nersting J: Mercaptopurine/Methotrexate maintenance therapy of
childhood acute lymphoblastic leukemia: Clinical facts and fiction.
J Pediatr Hematol Oncol. 36:503–517. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Burnett AK, Milligan D, Prentice AG,
Goldstone AH, McMullin MF, Hills RK and Wheatley K: A comparison of
low-dose cytarabine and hydroxyurea with or without all-trans
retinoic acid for acute myeloid leukemia and high-risk
myelodysplastic syndrome in patients not considered fit for
intensive treatment. Cancer. 109:1114–1124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huguet F and Tavitian S: Emerging
biological therapies to treat acute lymphoblastic leukemia. Expert
Opin Emerg Drugs. 22:107–121. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pan Y, Zhou F, Zhang R and Claret FX:
Stat3 inhibitor stattic exhibits potent antitumor activity and
induces chemo- and radio-sensitivity in nasopharyngeal carcinoma.
PLoS One. 8:e545652013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Buettner R, Mora LB and Jove R: Activated
STAT signaling in human tumors provides novel molecular targets for
therapeutic intervention. Clin Cancer Res. 8:945–954.
2002.PubMed/NCBI
|
|
20
|
Zhang Q, Zhang C, He J, Guo Q, Hu D, Yang
X, Wang J, Kang Y, She R, Wang Z, et al: STAT3 inhibitor stattic
enhances radiosensitivity in esophageal squamous cell carcinoma.
Tumour Biol. 36:2135–2142. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Schust J, Sperl B, Hollis A, Mayer TU and
Berg T: Stattic: A small-molecule inhibitor of STAT3 activation and
dimerization. Chem Biol. 13:1235–1242. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lin L, Liu A, Peng Z, Lin HJ, Li PK, Li C
and Lin J: STAT3 is necessary for proliferation and survival in
colon cancer-initiating cells. Cancer Res. 71:7226–7237. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kanna R, Choudhary G, Ramachandra N,
Steidl U, Verma A and Shastri A: STAT3 inhibition as a therapeutic
strategy for leukemia. Leuk Lymphoma. 59:2068–2074. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li CH, Xu LL, Jian LL, Yu RH, Zhao JX, Sun
L, Du GH and Liu XY: Stattic inhibits RANKL-mediated
osteoclastogenesis by suppressing activation of STAT3 and NF-κB
pathways. Int immunopharmacol. 58:136–144. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mikyskova R, Sapega O, Psotka M, Novotny
O, Hodny Z, Balintova S, Malinak D, Svobodova J, Andrys R, Rysanek
D, et al: STAT3 inhibitor Stattic and its analogues inhibit STAT3
phosphorylation and modulate cytokine secretion in senescent tumour
cells. Mol Med Rep. 27:812023. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Debnath J, Gammoh N and Ryan KM: Autophagy
and autophagy-related pathways in cancer. Nat Rev Mol Cell Biol.
24:560–575. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Huang L, Zhao Y, Shan M, Wang S, Chen J,
Liu Z and Xu Q: Targeting crosstalk of STAT3 between
tumor-associated M2 macrophages and Tregs in colorectal cancer.
Cancer Biol Ther. 24:22264182023. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yue P, Zhu Y, Brotherton-Pleiss C, Fu W,
Verma N, Chen J, Nakamura K, Chen W, Chen Y, Alonso-Valenteen F, et
al: Novel potent azetidine-based compounds irreversibly inhibit
Stat3 activation and induce antitumor response against human breast
tumor growth in vivo. Cancer Lett. 534:2156132022.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang L, Alizadeh D, Van Handel M,
Kortylewski M, Yu H and Badie B: Stat3 inhibition activates tumor
macrophages and abrogates glioma growth in mice. Glia.
57:1458–1467. 2009. View Article : Google Scholar : PubMed/NCBI
|
